The phase-I study of a therapeutic vaccine to ATL patients with autologous dendritic cells pulsed with peptides corresponding to Tax-specific CTL epitopes by Youko Suehiro et al.
ORAL PRESENTATION Open Access
The phase-I study of a therapeutic vaccine to ATL
patients with autologous dendritic cells pulsed
with peptides corresponding to Tax-specific
CTL epitopes
Youko Suehiro1*, Atsuhiko Hasegawa2, Tadafumi Iino3, Amane Sasada2, Nobukazu Watanabe4, Ilseung Choi1,
Tetsuya Fukuda5, Shigeo Takaishi6, Ryuji Tanosaki7, Atae Utsunomiya8, Osamu Miura5, Masao Matsuoka9,
Takanori Teshima10, Koichi Akashi3, Jun Okamura11, Mari Kannagi2, Naokuni Uike1
From 16th International Conference on Human Retroviruses: HTLV and Related Viruses
Montreal, Canada. 26-30 June 2013
In the last decade, various kinds of clinical trials of hema-
topoietic stem cell transplantation (HSCT) have been
performed for ATL patients, and showed therapeutic
effects with long-term remission in a part of recipients.
Our previous finding of activation of CD8+ Tax-specific
cytotoxic T-lymphocytes (CTL) in post-HSCT ATL
patients indicated the presence of Tax expression in vivo
and potential contributions of CTL to GVL effects. These
findings let us attempt developing an anti-ATL therapeu-
tic vaccine consisting of autologous dendritic cells (DC)
pulsed with Tax peptides corresponding to the major epi-
topes of Tax-specific CTL previously identified from
HLA-A2, A24 or A11-possessing post-HSCT ATL
patients. In preliminary experiments, the DC induced
with a conventional method showed matured phenotype
and produced IL-12 in 2 of 3 ATL patients tested. Under
the official approval by the institutional ethical commit-
tees, we conducted the phase-I clinical study of anti-ATL
immunotherapy for ATL patients at stable conditions
after other therapy. The peptide-pulsed DC was subcuta-
neously injected for three times with 2 weeks intervals.
The first patient showed a significant reduction in
the proviral loads in 1 week after administration of
DC, which gradually increase during the treatment, then
decreased again at 8 weeks after the initiation of the
therapy. Reduction in the size of surface lymph nodes by
CT confirmed the therapeutic effects. So far two patients
completed the course of the study without severe side
effects except for fever and skin rash, and their clinical
outcomes were partial remission and stable disease
respectively.
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